Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis

Autores
Petta, Salvatore; Kim, KyeongJin; Targher, Giovanni; Romeo, Stefano; Sookoian, Silvia Cristina; Zheng, Ming?Hua; Aghemo, Alessio; Valenti, Luca
Año de publicación
2025
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Semaglutide has recently received conditional accelerated approval in the US for treatment of metabolic dysfunction-associated steatohepatitis (MASH) with significant or advanced liver fibrosis (stage F2/F3). Phase 2 and 3 clinical trials show that subcutaneous semaglutide 2.4 mg/week leads to significant improvements in hepatic steatosis, disease activity, resolution of MASH and reduction in liver fibrosis. These benefits parallel weight loss and are accompanied by improved metabolic outcomes, including better glucose control and lipid profiles, as well as consistent benefits for cardiovascular and renal health. The treatment's safety profile is manageable, with gastrointestinal issues being the most frequent side effects, and no new safety concerns have been identified. Data on long-term tolerability, treatment retention and clinical events are now awaited in people with MASH fibrosis. The evidence regarding semaglutide's ability to directly target the liver and improve liver damage in cirrhosis, and its impact on muscle mass in at-risk populations, remains limited. Thus, in patients with advanced disease, it should be viewed primarily as a therapy that modifies metabolic disease. Practically, semaglutide is most suitable as a first-line treatment to prevent liver complications for people with MASH and stage F2/F3 fibrosis with severe metabolic dysfunction, obesity, or type 2 diabetes who could benefit from both liver and cardiovascular-renal improvements. Treatment should be tailoured to each individual, with ongoing monitoring of body weight, serum aminotransferase levels and direct measurement of liver fat and stiffness to guide therapy.
Fil: Petta, Salvatore. Università degli Studi di Palermo; Italia
Fil: Kim, KyeongJin. Inha University; Corea del Sur
Fil: Targher, Giovanni. Universita di Verona; Italia
Fil: Romeo, Stefano. Karolinska University Hospital; Suecia
Fil: Sookoian, Silvia Cristina. Centro de Investigacion Traslacional En Salud (cenitres) ; Facultad de Cs. de la Salud ; Universidad Maimonides; . Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Zheng, Ming?Hua. The First Affiliated Hospital Of Wenzhou Medical; China
Fil: Aghemo, Alessio. Humanitas University; Italia
Fil: Valenti, Luca. Politecnico di Milano; Italia
Materia
MASH
MASLD
SEMAGLUTIDE
FIBROSIS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/279444
Acceder
id CONICETDig_d87e3a2de0e26245fbf7dd09a4a92092
oai_identifier_str oai:ri.conicet.gov.ar:11336/279444
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated SteatohepatitisPetta, SalvatoreKim, KyeongJinTargher, GiovanniRomeo, StefanoSookoian, Silvia CristinaZheng, Ming?HuaAghemo, AlessioValenti, LucaMASHMASLDSEMAGLUTIDEFIBROSIShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Semaglutide has recently received conditional accelerated approval in the US for treatment of metabolic dysfunction-associated steatohepatitis (MASH) with significant or advanced liver fibrosis (stage F2/F3). Phase 2 and 3 clinical trials show that subcutaneous semaglutide 2.4 mg/week leads to significant improvements in hepatic steatosis, disease activity, resolution of MASH and reduction in liver fibrosis. These benefits parallel weight loss and are accompanied by improved metabolic outcomes, including better glucose control and lipid profiles, as well as consistent benefits for cardiovascular and renal health. The treatment's safety profile is manageable, with gastrointestinal issues being the most frequent side effects, and no new safety concerns have been identified. Data on long-term tolerability, treatment retention and clinical events are now awaited in people with MASH fibrosis. The evidence regarding semaglutide's ability to directly target the liver and improve liver damage in cirrhosis, and its impact on muscle mass in at-risk populations, remains limited. Thus, in patients with advanced disease, it should be viewed primarily as a therapy that modifies metabolic disease. Practically, semaglutide is most suitable as a first-line treatment to prevent liver complications for people with MASH and stage F2/F3 fibrosis with severe metabolic dysfunction, obesity, or type 2 diabetes who could benefit from both liver and cardiovascular-renal improvements. Treatment should be tailoured to each individual, with ongoing monitoring of body weight, serum aminotransferase levels and direct measurement of liver fat and stiffness to guide therapy.Fil: Petta, Salvatore. Università degli Studi di Palermo; ItaliaFil: Kim, KyeongJin. Inha University; Corea del SurFil: Targher, Giovanni. Universita di Verona; ItaliaFil: Romeo, Stefano. Karolinska University Hospital; SueciaFil: Sookoian, Silvia Cristina. Centro de Investigacion Traslacional En Salud (cenitres) ; Facultad de Cs. de la Salud ; Universidad Maimonides; . Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Zheng, Ming?Hua. The First Affiliated Hospital Of Wenzhou Medical; ChinaFil: Aghemo, Alessio. Humanitas University; ItaliaFil: Valenti, Luca. Politecnico di Milano; ItaliaWiley Blackwell Publishing, Inc2025-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/279444Petta, Salvatore; Kim, KyeongJin; Targher, Giovanni; Romeo, Stefano; Sookoian, Silvia Cristina; et al.; Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis; Wiley Blackwell Publishing, Inc; Liver International; 45; 11; 10-2025; 1-121478-3223CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1111/liv.70407info:eu-repo/semantics/altIdentifier/doi/10.1111/liv.70407info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-02-26T10:35:42Zoai:ri.conicet.gov.ar:11336/279444instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-02-26 10:35:42.998CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis
title Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis
spellingShingle Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis
Petta, Salvatore
MASH
MASLD
SEMAGLUTIDE
FIBROSIS
title_short Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis
title_full Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis
title_fullStr Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis
title_full_unstemmed Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis
title_sort Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis
dc.creator.none.fl_str_mv Petta, Salvatore
Kim, KyeongJin
Targher, Giovanni
Romeo, Stefano
Sookoian, Silvia Cristina
Zheng, Ming?Hua
Aghemo, Alessio
Valenti, Luca
author Petta, Salvatore
author_facet Petta, Salvatore
Kim, KyeongJin
Targher, Giovanni
Romeo, Stefano
Sookoian, Silvia Cristina
Zheng, Ming?Hua
Aghemo, Alessio
Valenti, Luca
author_role author
author2 Kim, KyeongJin
Targher, Giovanni
Romeo, Stefano
Sookoian, Silvia Cristina
Zheng, Ming?Hua
Aghemo, Alessio
Valenti, Luca
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv MASH
MASLD
SEMAGLUTIDE
FIBROSIS
topic MASH
MASLD
SEMAGLUTIDE
FIBROSIS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Semaglutide has recently received conditional accelerated approval in the US for treatment of metabolic dysfunction-associated steatohepatitis (MASH) with significant or advanced liver fibrosis (stage F2/F3). Phase 2 and 3 clinical trials show that subcutaneous semaglutide 2.4 mg/week leads to significant improvements in hepatic steatosis, disease activity, resolution of MASH and reduction in liver fibrosis. These benefits parallel weight loss and are accompanied by improved metabolic outcomes, including better glucose control and lipid profiles, as well as consistent benefits for cardiovascular and renal health. The treatment's safety profile is manageable, with gastrointestinal issues being the most frequent side effects, and no new safety concerns have been identified. Data on long-term tolerability, treatment retention and clinical events are now awaited in people with MASH fibrosis. The evidence regarding semaglutide's ability to directly target the liver and improve liver damage in cirrhosis, and its impact on muscle mass in at-risk populations, remains limited. Thus, in patients with advanced disease, it should be viewed primarily as a therapy that modifies metabolic disease. Practically, semaglutide is most suitable as a first-line treatment to prevent liver complications for people with MASH and stage F2/F3 fibrosis with severe metabolic dysfunction, obesity, or type 2 diabetes who could benefit from both liver and cardiovascular-renal improvements. Treatment should be tailoured to each individual, with ongoing monitoring of body weight, serum aminotransferase levels and direct measurement of liver fat and stiffness to guide therapy.
Fil: Petta, Salvatore. Università degli Studi di Palermo; Italia
Fil: Kim, KyeongJin. Inha University; Corea del Sur
Fil: Targher, Giovanni. Universita di Verona; Italia
Fil: Romeo, Stefano. Karolinska University Hospital; Suecia
Fil: Sookoian, Silvia Cristina. Centro de Investigacion Traslacional En Salud (cenitres) ; Facultad de Cs. de la Salud ; Universidad Maimonides; . Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Zheng, Ming?Hua. The First Affiliated Hospital Of Wenzhou Medical; China
Fil: Aghemo, Alessio. Humanitas University; Italia
Fil: Valenti, Luca. Politecnico di Milano; Italia
description Semaglutide has recently received conditional accelerated approval in the US for treatment of metabolic dysfunction-associated steatohepatitis (MASH) with significant or advanced liver fibrosis (stage F2/F3). Phase 2 and 3 clinical trials show that subcutaneous semaglutide 2.4 mg/week leads to significant improvements in hepatic steatosis, disease activity, resolution of MASH and reduction in liver fibrosis. These benefits parallel weight loss and are accompanied by improved metabolic outcomes, including better glucose control and lipid profiles, as well as consistent benefits for cardiovascular and renal health. The treatment's safety profile is manageable, with gastrointestinal issues being the most frequent side effects, and no new safety concerns have been identified. Data on long-term tolerability, treatment retention and clinical events are now awaited in people with MASH fibrosis. The evidence regarding semaglutide's ability to directly target the liver and improve liver damage in cirrhosis, and its impact on muscle mass in at-risk populations, remains limited. Thus, in patients with advanced disease, it should be viewed primarily as a therapy that modifies metabolic disease. Practically, semaglutide is most suitable as a first-line treatment to prevent liver complications for people with MASH and stage F2/F3 fibrosis with severe metabolic dysfunction, obesity, or type 2 diabetes who could benefit from both liver and cardiovascular-renal improvements. Treatment should be tailoured to each individual, with ongoing monitoring of body weight, serum aminotransferase levels and direct measurement of liver fat and stiffness to guide therapy.
publishDate 2025
dc.date.none.fl_str_mv 2025-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/279444
Petta, Salvatore; Kim, KyeongJin; Targher, Giovanni; Romeo, Stefano; Sookoian, Silvia Cristina; et al.; Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis; Wiley Blackwell Publishing, Inc; Liver International; 45; 11; 10-2025; 1-12
1478-3223
CONICET Digital
CONICET
url http://hdl.handle.net/11336/279444
identifier_str_mv Petta, Salvatore; Kim, KyeongJin; Targher, Giovanni; Romeo, Stefano; Sookoian, Silvia Cristina; et al.; Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis; Wiley Blackwell Publishing, Inc; Liver International; 45; 11; 10-2025; 1-12
1478-3223
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1111/liv.70407
info:eu-repo/semantics/altIdentifier/doi/10.1111/liv.70407
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley Blackwell Publishing, Inc
publisher.none.fl_str_mv Wiley Blackwell Publishing, Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1858306303092326400
score 12.665996

Publicaciones similares